GenSight Biologics S.A.: GenSight Biologics Reports Full Year 2022 Consolidated Financial Results

Efforts to reduce cash burn in 2023 while securing LUMEVOQ manufacturing and preparing for commercial launch in Europe in H1 2024 PPQ campaign to start early May 2023 with results expected

Related Keywords

United Kingdom ,United States ,Italy ,Germany ,Spain ,France ,French ,Clothilde Caillet ,Gensight Biologics ,Guillaume Van Renterghem ,James Palmer ,Thomas Gidoin ,Jeanene Timberlake ,Euronext ,Corporate Communications ,Sight Biologics ,Universal Registration Document ,Des March ,Chief Financial Officer ,Consolidated Financial Statements ,Year Ending December ,Temporary Authorizations ,Early Access Authorisation ,Good Manufacturing Practices ,Marketing Authorisation Application ,Heights Capital ,Sight Biologic ,Mitochondrial Targeting Sequence ,Leber Hereditary Optic Neuropathy ,Gensight Biologic ,Communications Director ,Diese Gold Aktie ,Sichern Sie ,Gensight ,Iologics ,Reports ,Bull ,Ear ,022 ,Onsolidated ,Financial ,Results ,